ETF Comparison
JNJ vs KO: Which Is the Better Pick in 2026?
A head-to-head comparison of Johnson & Johnson and The Coca-Cola Company covering yield, cost, risk, and income potential.
Data updated May 20, 2026
Side-by-side snapshot
| JNJ | KO | |
|---|---|---|
| Full name | Johnson & Johnson | The Coca-Cola Company |
| Issuer | — | — |
| Last Close | $228.92 as of May 20, 2026 | $81.20 as of May 20, 2026 |
| Distribution yield | 2.27% | 2.51% |
| Expense ratio | — | — |
| AUM | — | — |
| Distribution frequency | Quarterly | Quarterly |
| Underlying index | — | — |
| Objective | Researches, develops, manufactures, and sells healthcare products including pharmaceuticals, medical devices, and consumer health products worldwide. | Manufactures, distributes, and markets nonalcoholic beverage concentrates, syrups, and finished beverages worldwide. |
| Asset class | Equity | Equity |
| Inception date | — | — |
| Last dividend | $1.30 | $0.53 |
| Ex-dividend date | 02/24/2026 | 03/13/2026 |
Income calculator
See how much monthly income a hypothetical investment would generate in each ETF at current yields.
Want to go deeper?
Add these ETFs to a sample portfolio and forecast your dividend income over 5+ years — no signup required.
Visual comparison
Key metrics
Projected income on $10K
Projections assume the current yield and share price remain constant. Actual results will vary.
Quick verdict
JNJ (Johnson & Johnson) and KO (The Coca-Cola Company) are both quarterly-pay dividend ETFs, but they take different approaches.
KO offers the higher yield at 2.51% vs 2.27% for JNJ. A higher yield means more current income per dollar invested, though it may come with different risk characteristics.
Deep dive
Yield & income
On a $10,000 investment, JNJ would generate roughly $18.92/month, while KO would produce $20.92/month, at current distribution rates. Both pay quarterly distributions.
Cost & efficiency
Over 10 years on $10,000, JNJ would cost approximately $0 in fees vs $0 for KO (simplified, not compounded). Both charge the same expense ratio.
Strategy & risk
JNJ tracks — with a dividend approach, while KO tracks — using a dividend strategy.
Fund details
JNJ is managed by — (launched —) with — in assets. KO is managed by — (launched —) with — in assets.
Enjoyed this page?
Do us a favor — if you found this comparison useful, please share it with a friend researching dividend ETFs.
Frequently asked questions
Is JNJ or KO better for dividend income?
It depends on your goals. KO currently offers the higher distribution yield, which means more income per dollar invested. However, a lower-yield fund may offer better total return or lower volatility. Consider your time horizon and risk tolerance.
What is the difference between JNJ and KO?
JNJ (Johnson & Johnson) tracks — with a dividend strategy, while KO (The Coca-Cola Company) tracks — with a dividend approach. They are issued by — and — respectively.
Can I hold both JNJ and KO?
Yes. Many income investors hold both to diversify across different strategies and underlying indexes. This can reduce concentration risk while maintaining a strong income stream.
Which has lower fees, JNJ or KO?
JNJ has an expense ratio of — while KO charges —. Lower fees mean more of your investment returns stay in your pocket over time.
How much income does $10,000 in JNJ vs KO generate?
At current rates, $10,000 in JNJ would generate roughly $18.92 per month ($227.00 annually). The same in KO would produce about $20.92 per month ($251.00 annually).
More comparisons to explore
People also compare KO with
Popular comparisons
JNJ vs KO — at a glance
Generated April 2026 from current fund data.
Overview
JNJ and KO are both mature, dividend-paying stocks from different sectors: JNJ operates in pharmaceuticals and medical devices globally, while KO manufactures and distributes nonalcoholic beverages. Both pay quarterly dividends and have yields below 3%, making them lower-risk income plays compared to higher-yielding vehicles. The key distinction is sector exposure—healthcare innovation versus consumer staples—which drives their earnings drivers and dividend sustainability profiles.
How they differ
JNJ yields 2.18% on a share price of $238.67; KO yields 2.71% at $75.31. KO's higher yield reflects its mature, slower-growth profile in beverages, where pricing power is constrained by competition and shifting consumer preferences toward healthier drinks. JNJ's lower yield reflects stronger organic growth potential from its pharmaceutical pipeline and medical-device franchise, historically more resilient during downturns. Both trade within reasonable distance of 52-week ranges—JNJ between $146–$252, KO between $65–$82—suggesting neither is in an extreme valuation position. Dividend frequency is identical (quarterly for both), so tax-reporting complexity is the same.
Who each is best for
JNJ: Long-term buy-and-hold investors in taxable accounts seeking steady dividend growth with moderate capital appreciation; healthcare-focused portfolios where pharma/device exposure is desired; those with lower immediate income needs but confidence in reinvestment over 10+ years.
KO: Dividend-income seekers prioritizing yield over growth; investors comfortable with slower earnings expansion in exchange for a well-established, globally recognized cash-generation machine; retirees or those in lower tax brackets where the 2.71% yield provides meaningful cash flow.
Key risks to know
- Regulatory and patent risk (JNJ): Pharmaceutical income depends on pipeline success and patent cliffs. Loss of exclusivity on major drugs can erode revenues and dividend-coverage ratios over 2–5 year windows.
- Consumer-demand risk (KO): Secular headwinds in sugary-beverage consumption in developed markets; success of sugar-free and functional-drink pivots is not guaranteed, and margin pressure from ingredient costs or tariffs could constrain payout growth.
- Valuation sensitivity: JNJ trades at a premium multiple to many healthcare peers; KO at a discount to food/beverage peers. Both are vulnerable to equity-market rotation if interest rates rise or investors favor growth over dividends.
- Concentration: Both are single-stock positions. Idiosyncratic event risk (product recalls, litigation, missed trials, geopolitical exposure) affects each independently.
Bottom line
If you want dividend growth and believe in long-cycle healthcare innovation, JNJ offers lower current yield but higher organic-growth potential. If you prioritize current income and accept slower growth, KO's 2.71% yield and established global distribution network may be more suitable. Past performance doesn't predict future results; both are defensive plays but face different sectoral headwinds.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
Model these ETFs in your own portfolio
Start a free Dividend Vision account to project monthly income, track overlap across holdings, and compare these funds against anything else in your portfolio.